The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ELCC 2018 | Therapy sequencing in the current NSCLC treatment landscape
In this video, recorded at the European Lung Cancer Congress (ELCC) 2018, held in Geneva, Switzerland, Nicolas Girard, MD, PhD, of Claude Bernard University, Lyon, France, discusses treatment sequencing for EGFR mutant non-small cell lung cancer (NSCLC). He speaks about the wide range of TKIs and immune checkpoint inhibitors available, and how new research and clinical understanding will illuminate the best way to use these therapies in relation to other treatments such as chemotherapy.
